Dr. Andrew G. Gianoukakis, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
21840 Normandie Ave, Ste. 700
Torrance, CA 90502
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 18
Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
CA license A79831 (first issued 2002; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Torrance Memorial Medical Center Torrance, CA
- Lac/harbor-UCLA Med Center Torrance, CA
Medical groups
- Prohealth PArtners, A Medical Group (239 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 18
- Services billed
- 75
- Patients’ average age
- 73
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Torrance, CA | 20 |
| Pravastatin Sodium Other prescribers in Torrance, CA | 12 |
| Jardiance (empagliflozin) Other prescribers in Torrance, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $1,656 in total to this clinician.
| Eisai Inc. | $1,656 |
|---|
| Consulting Fee | $1,563 |
|---|---|
| Food and Beverage | $93.01 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Feb 26, 2025 | Consulting Fee Lenvima · Oncology | $1,563 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $44,415 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blinded, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Radioiodine Refractory Defferentiated Thyroid Cancer who have Progressed after Prior VEGFR Targeted Therapy
Exelixis Inc. - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Eli Lilly and Company · Active, not recruiting · NCT04211337 - Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.